[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. 1995

T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
Department of Pediatrics, School of Medicine Kurume University.

Pharmacokinetic, bacteriological and clinical studies on SY5555, a new oral penem, were carried out, and the following results were obtained. 1. MICs were determined for 6 drugs, SY5555, clavulanic acid/amoxicillin (CVA/AMPC), cefaclor (CCL), cefotiam (CTM), cefpodoxime (CPDX), cefdinir (CFDN) against 20 strains of bacteria isolated from patients who were subsequently treated with SY5555. MICs of SY5555 for Gram-positive cocci ranged from 0.05 to 0.10 microgram/ml against 10 strains of Staphylococcus aureus. The MIC was < or = 0.025 microgram/ml against one strain of Streptococcus pyogenes, and MICs were from < or = 0.025 to 0.39 microgram/ml against Streptococcus pneumoniae. These MIC values were equivalent or superior to those of the other 5 drugs. MICs of SY5555 for Gram-negative bacilli were 0.39 and 6.25 micrograms/ml against Haemophilus influenzae, and these values were equivalent to those of the other drugs, except CPDX. The MIC of SY5555 was 0.39 microgram/ml against 2 strains of Escherichia coli, and this value was equivalent or superior to those of CVA/AMPC and CCL, similar or inferior to those of CPDX and CFDN, and inferior to that of CTM. The MICs of several drugs were determined for 10 strains of Bordetella pertussis and 30 strains of Campylobacter jejuni isolated from patients before this clinical study. The MICs of SY5555 against the 10 strains of B. pertussis were compared with those of 7 drugs, CCL, CTM, CPDX, ampicillin (ABPC), piperacillin (PIPC), imipenem (IPM) and erythromycin (EM). The MIC of SY5555 was 0.78 microgram/ml against all of the strains. This value was superior to those of CCL, CTM and CPDX, similar or inferior to that of IPM and inferior to those of PIPC and EM. The MICs of SY5555 against the 30 strains of C. jejuni were compared with those of 7 drugs. CCL, CTM, CPDX, CFDN, ABPC, IPM and EM, and the MIC of SY5555 was < or = 0.025 microgram/ml or 0.05 microgram/ml and these values were equivalent or superior to those of the 7 reference drugs. 2. SY5555 dry syrup was administered orally at 30 min. after meals, to a total of 5 patients, at doses of 5.0 and 10.0 mg/kg to 2 patients each and at a dose of 15.0 mg/kg to one patient and the plasma concentrations were determined. Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011208 Powders Substances made up of an aggregation of small particles, as that obtained by grinding or trituration of a solid drug. In pharmacy it is a form in which substances are administered. (From Dorland, 28th ed) Powder
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria

Related Publications

T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
January 1995, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
February 1995, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
April 1994, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
January 1995, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
February 1989, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
May 1990, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
March 1989, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
July 1993, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
March 1989, The Japanese journal of antibiotics,
T Motohiro, and S Handa, and S Yamada, and S Oki, and Y Yoshinaga, and K Oda, and Y Sakata, and H Kato, and F Yamashita, and S Imai
August 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!